Clinical Core
Clifford Deutschman, MD, MS, MCCM
Vice-Chair, Research
Northwell School of Medicine and the Feinstein Institute for Medical Research
Halesite, NY
Disclosure(s): Enlivex Inc: Consultant (Ongoing); La Jolla Pharmaceuticals: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing)
Sepsis and septic shock, which killed over 19 million people globally in 2017, are the leading causes of death in hospitalized patients in the United States. Over 30 clinical trials have failed to improve mortality, highlighting the need for targeted sepsis therapies. Within hours of sepsis onset, the systemic inflammatory response transitions from a hyperinflammatory to a persistent hypoinflammatory and immunosuppressive starvation-like state, coexistent with multiorgan dysfunction. Clinical alignment with these states is challenging, emphasizing the unmet need for biochemically relevant biomarkers and their kinetic values. The goal of this session is to discuss the biochemical/metabolic drivers of such transition and their role as biomarkers and targets for phase-specific molecular therapies for sepsis.
Concurrent Session Faculty: Vidula T. Vachharajani, MD, FCCP, FCCM – Cleveland Clinic Lerner College of Medicine
Concurrent Session Faculty: Scott L. Weiss, MD, FCCM – The Children's Hospital of Philadelphia
Concurrent Session Faculty: Paul E. Wischmeyer, MD, EDIC, FASPEN – Duke University School of Medicine